<DOC>
	<DOCNO>NCT01674569</DOCNO>
	<brief_summary>The objective study evaluate safety preliminary biologic activity/efficacy X-82 patient wet Age-related Macular Degeneration ( AMD ) . Preliminary efficacy assess change baseline visual acuity , fluorescein leakage , retinal thickness fibrosis , detectable , base fundus examination , fundus photography , fluorescein angiography optical coherence tomography ( OCT ) .</brief_summary>
	<brief_title>Pilot Study X-82 Patients With Wet AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Active choroidal neovascularization ( CNV ) associate AMD , evidence fluorescein angiography ( FA ) OCT. 2 . No previous treatment antiVEGF therapy prior antiVEGF therapy evidence response treatment need additional treatment . 3 . Early Treatment Diabetic Retinopathy Study ( ETDRS ) BCVA 20/32 20/320 study eye ( ) . 4 . Adequate bone marrow function . 5 . PT within institutional upper limit normal . 6 . Adequate hepatic function . 7 . Adequate renal function ; serum creatinine . 8 . Ability swallow oral medication . 9 . Age ≥ 50 year . 10 . Willing able provide write informed consent , comply investigational study protocol return study visit . 1 . Previous treatment photodynamic therapy ( PDT ) within 4 month screen study eye . 2 . CNV due cause AMD . 3 . Geographic atrophy involve foveal center study eye . 4 . Any retinal vascular disease retinal degeneration AMD study eye . 5 . In opinion investigator , significant disease study eye could compromise bestcorrected visual acuity . 6 . Cataract surgery study eye within three month screen . 7 . Trabeculectomy aqueous shunt valve study eye . 8 . Intraocular surgery study eye within three month screen ; Nd : YAG capsulotomy laser iridotomy within 30 day screen . 9 . Inadequate pupillary dilation significant medium opacity study eye . 10 . Use investigational agent participation clinical trial investigational agent investigational therapy within thirty ( 30 ) day baseline exception subject participate AREDS2 study . 11 . Females child bear potential pregnant use medically acceptable contraception ; male unwilling take adequate contraceptive measure . Females breastfeed also exclude . 12 . Serious allergy prior significant adverse reaction fluorescein . 13 . Undiagnosed acute illness first observe screen screen baseline , severe concurrent medical condition , investigator judgment , represent safety concern . 14 . Severe cardiac disease , symptomatic congestive heart failure , unstable angina , acute coronary syndrome , myocardial infarction coronary artery revascularization , arterial thrombosis within 12 month start study drug , inadequately control hypertension , ventricular tachyarrhythmias require ongoing treatment . 15 . QTc ≥450 msec subject history risk factor Torsades de Pointes clinically significant ECG abnormality determine investigator . 16 . Stroke transient ischemic attack within 12 month trial entry . 17 . Clinically significant impair renal hepatic function . 18 . Any major surgical procedure within one month trial entry . 19 . Presence active gastrointestinal ( GI ) disease condition interfere significantly absorption , distribution , metabolism , excretion X82 . 20 . Receiving treatment anticoagulant 325 mg aspirin per day . 21 . Serious active infection , serious medical condition condition would impair ability subject administer investigational drug adhere study protocol requirement . 22 . Presence condition , judgment investigator , would prevent subject complete study . 23 . No herbal medication exception bilberry allow within 7 day start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>VEGF</keyword>
	<keyword>PDGF</keyword>
	<keyword>AMD</keyword>
</DOC>